ABT 555

Drug Profile

ABT 555

Alternative Names: ABT-555

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Immunomodulators; Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 06 Feb 2017 AbbVie terminates a phase I trial in Multiple sclerosis in United Kingdom (NCT02606630)
  • 18 Oct 2016 Abbvie suspends enrolment in a phase I trial for Multiple sclerosis in United Kingdom (NCT02606630)
  • 14 Sep 2016 Adverse events, pharmacodynamic and pharmacokinetic data from phase I study in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top